Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, T-Cell, Peripheral | 13 | 2022 | 122 | 4.650 |
Why?
|
Lymphoma, Mantle-Cell | 7 | 2020 | 211 | 2.320 |
Why?
|
Lymphoma, Follicular | 6 | 2022 | 405 | 1.760 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 13 | 2021 | 1264 | 1.650 |
Why?
|
Immunoconjugates | 5 | 2022 | 831 | 1.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2022 | 11253 | 1.200 |
Why?
|
Stem Cell Transplantation | 11 | 2022 | 1660 | 1.160 |
Why?
|
Lymphoma, T-Cell | 7 | 2022 | 296 | 1.110 |
Why?
|
Hematopoietic Stem Cell Transplantation | 15 | 2022 | 5135 | 1.090 |
Why?
|
Histiocytosis, Sinus | 3 | 2021 | 48 | 1.050 |
Why?
|
Lymphoma, Non-Hodgkin | 11 | 2019 | 1330 | 0.910 |
Why?
|
Immunoblastic Lymphadenopathy | 3 | 2022 | 38 | 0.790 |
Why?
|
Histiocytosis, Langerhans-Cell | 5 | 2021 | 174 | 0.720 |
Why?
|
Histiocytosis | 1 | 2018 | 38 | 0.710 |
Why?
|
Transplantation, Autologous | 13 | 2022 | 2092 | 0.710 |
Why?
|
Mycosis Fungoides | 2 | 2020 | 153 | 0.550 |
Why?
|
Drug Resistance, Neoplasm | 11 | 2019 | 5197 | 0.550 |
Why?
|
Skin Diseases | 3 | 2020 | 1088 | 0.540 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 3 | 2021 | 46 | 0.540 |
Why?
|
Erdheim-Chester Disease | 3 | 2021 | 10 | 0.540 |
Why?
|
Pyrazoles | 5 | 2021 | 1954 | 0.530 |
Why?
|
Lymphoma | 5 | 2016 | 1871 | 0.520 |
Why?
|
Pyrimidines | 6 | 2021 | 2950 | 0.520 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 985 | 0.510 |
Why?
|
Neoplasm Proteins | 5 | 2021 | 3773 | 0.510 |
Why?
|
Hodgkin Disease | 6 | 2022 | 1412 | 0.510 |
Why?
|
Hematologic Neoplasms | 3 | 2021 | 1687 | 0.490 |
Why?
|
Sirolimus | 5 | 2015 | 1571 | 0.450 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2021 | 1487 | 0.450 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2019 | 166 | 0.430 |
Why?
|
Antineoplastic Agents | 16 | 2021 | 13714 | 0.420 |
Why?
|
Transplantation Conditioning | 6 | 2022 | 1553 | 0.420 |
Why?
|
Skin Neoplasms | 4 | 2021 | 5266 | 0.410 |
Why?
|
Sezary Syndrome | 1 | 2011 | 76 | 0.400 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2022 | 8877 | 0.390 |
Why?
|
Enteritis | 1 | 2011 | 158 | 0.390 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1667 | 0.390 |
Why?
|
Histiocytes | 2 | 2021 | 104 | 0.370 |
Why?
|
Disease-Free Survival | 14 | 2019 | 7026 | 0.360 |
Why?
|
Cytarabine | 3 | 2020 | 689 | 0.350 |
Why?
|
Busulfan | 2 | 2022 | 271 | 0.350 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 7 | 2013 | 726 | 0.340 |
Why?
|
Bone Marrow Purging | 2 | 2004 | 113 | 0.340 |
Why?
|
Mutation | 8 | 2020 | 29262 | 0.330 |
Why?
|
Remission Induction | 8 | 2018 | 2399 | 0.310 |
Why?
|
T-Lymphocytes | 5 | 2021 | 10362 | 0.300 |
Why?
|
Genomics | 2 | 2018 | 5300 | 0.290 |
Why?
|
Graft vs Host Disease | 4 | 2015 | 2818 | 0.280 |
Why?
|
Humans | 90 | 2022 | 708843 | 0.280 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2020 | 202 | 0.280 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 5405 | 0.270 |
Why?
|
Salvage Therapy | 7 | 2019 | 1296 | 0.270 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2118 | 0.260 |
Why?
|
Immune Tolerance | 1 | 2013 | 2333 | 0.260 |
Why?
|
Burkitt Lymphoma | 1 | 2006 | 362 | 0.250 |
Why?
|
Epididymis | 1 | 2005 | 231 | 0.250 |
Why?
|
Middle Aged | 49 | 2022 | 213752 | 0.250 |
Why?
|
Antibodies, Monoclonal | 5 | 2013 | 9584 | 0.250 |
Why?
|
Survival Rate | 9 | 2017 | 13202 | 0.240 |
Why?
|
Recurrence | 10 | 2019 | 8255 | 0.240 |
Why?
|
Aged | 46 | 2021 | 161488 | 0.240 |
Why?
|
Benzamides | 2 | 2019 | 1406 | 0.230 |
Why?
|
Pyrazines | 2 | 2019 | 1259 | 0.230 |
Why?
|
Kidney | 1 | 2017 | 6888 | 0.220 |
Why?
|
Adult | 44 | 2021 | 211041 | 0.220 |
Why?
|
Male | 52 | 2021 | 349524 | 0.210 |
Why?
|
Aged, 80 and over | 24 | 2021 | 58184 | 0.210 |
Why?
|
STAT Transcription Factors | 1 | 2021 | 155 | 0.210 |
Why?
|
Transplantation, Homologous | 7 | 2018 | 4831 | 0.210 |
Why?
|
Hydroxamic Acids | 3 | 2018 | 507 | 0.210 |
Why?
|
Melphalan | 1 | 2022 | 385 | 0.210 |
Why?
|
Janus Kinases | 1 | 2021 | 209 | 0.210 |
Why?
|
Mechlorethamine | 1 | 2020 | 139 | 0.200 |
Why?
|
Pyrimethamine | 1 | 2021 | 95 | 0.200 |
Why?
|
Cyclophosphamide | 4 | 2013 | 2189 | 0.200 |
Why?
|
Alkylating Agents | 1 | 2020 | 130 | 0.200 |
Why?
|
Hematopoietic Stem Cell Mobilization | 2 | 2012 | 222 | 0.190 |
Why?
|
Isoquinolines | 2 | 2019 | 385 | 0.190 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 19 | 0.190 |
Why?
|
Heterocyclic Compounds | 2 | 2012 | 271 | 0.190 |
Why?
|
Testicular Neoplasms | 1 | 2005 | 751 | 0.190 |
Why?
|
Symporters | 1 | 2022 | 366 | 0.180 |
Why?
|
Female | 49 | 2021 | 375205 | 0.180 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2018 | 2971 | 0.180 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2018 | 2498 | 0.180 |
Why?
|
Histiocytic Sarcoma | 1 | 2019 | 46 | 0.180 |
Why?
|
Treatment Outcome | 24 | 2021 | 61932 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 2 | 2018 | 384 | 0.170 |
Why?
|
Tumor Escape | 1 | 2021 | 328 | 0.170 |
Why?
|
Vincristine | 3 | 2013 | 1039 | 0.170 |
Why?
|
Prognosis | 10 | 2022 | 28919 | 0.170 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2012 | 637 | 0.170 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1454 | 0.160 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2018 | 438 | 0.160 |
Why?
|
Nitriles | 1 | 2021 | 950 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 338 | 0.150 |
Why?
|
Clinical Trials as Topic | 5 | 2020 | 8024 | 0.150 |
Why?
|
Adenine | 3 | 2018 | 916 | 0.150 |
Why?
|
Neoplasm Staging | 6 | 2019 | 11126 | 0.150 |
Why?
|
STAT3 Transcription Factor | 1 | 2021 | 895 | 0.150 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2014 | 803 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 200 | 0.150 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 534 | 0.140 |
Why?
|
Breast Implants | 1 | 2019 | 356 | 0.140 |
Why?
|
Prednisone | 3 | 2013 | 1556 | 0.140 |
Why?
|
Methotrexate | 2 | 2015 | 1708 | 0.140 |
Why?
|
Follow-Up Studies | 8 | 2019 | 39038 | 0.140 |
Why?
|
Disease Management | 4 | 2019 | 2536 | 0.140 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1241 | 0.140 |
Why?
|
Tissue Banks | 1 | 2016 | 198 | 0.140 |
Why?
|
Purines | 1 | 2019 | 600 | 0.140 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 2878 | 0.140 |
Why?
|
Young Adult | 17 | 2021 | 55940 | 0.140 |
Why?
|
Nose Neoplasms | 1 | 2017 | 244 | 0.140 |
Why?
|
Retreatment | 1 | 2016 | 628 | 0.140 |
Why?
|
B-Lymphocytes | 3 | 2021 | 4861 | 0.130 |
Why?
|
MAP Kinase Signaling System | 2 | 2020 | 1588 | 0.130 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 107 | 0.130 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2020 | 1922 | 0.130 |
Why?
|
Neoplasm, Residual | 4 | 2022 | 996 | 0.130 |
Why?
|
Vidarabine | 1 | 2015 | 348 | 0.130 |
Why?
|
Sequence Deletion | 1 | 2018 | 1548 | 0.130 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1380 | 0.130 |
Why?
|
Immunotherapy, Adoptive | 2 | 2021 | 1017 | 0.120 |
Why?
|
Bone Marrow Neoplasms | 1 | 2014 | 108 | 0.120 |
Why?
|
Doxorubicin | 3 | 2013 | 2235 | 0.120 |
Why?
|
DNA Mutational Analysis | 3 | 2017 | 4317 | 0.120 |
Why?
|
Arabinonucleosides | 1 | 2013 | 35 | 0.120 |
Why?
|
Piperidines | 3 | 2018 | 1582 | 0.120 |
Why?
|
Adenine Nucleotides | 1 | 2013 | 128 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2018 | 1399 | 0.120 |
Why?
|
Enzyme Inhibitors | 2 | 2019 | 3936 | 0.120 |
Why?
|
ras Proteins | 1 | 2019 | 1116 | 0.120 |
Why?
|
Fatigue | 2 | 2017 | 1450 | 0.120 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 359 | 0.120 |
Why?
|
Leukopenia | 1 | 2012 | 216 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 9488 | 0.110 |
Why?
|
Carmustine | 1 | 2012 | 144 | 0.110 |
Why?
|
Thiophenes | 1 | 2016 | 597 | 0.110 |
Why?
|
Aminopterin | 1 | 2011 | 16 | 0.110 |
Why?
|
Tacrolimus | 1 | 2015 | 717 | 0.110 |
Why?
|
Gastroesophageal Reflux | 1 | 2017 | 701 | 0.110 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1853 | 0.110 |
Why?
|
Immunohistochemistry | 2 | 2016 | 11790 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3714 | 0.100 |
Why?
|
Folic Acid Antagonists | 1 | 2011 | 81 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 1004 | 0.100 |
Why?
|
Etoposide | 1 | 2012 | 631 | 0.100 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1513 | 0.100 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 13274 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1400 | 0.090 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2011 | 145 | 0.090 |
Why?
|
Attitude to Health | 1 | 2019 | 2102 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 654 | 0.090 |
Why?
|
Stem Cells | 1 | 2022 | 3593 | 0.090 |
Why?
|
Skin | 2 | 2020 | 4325 | 0.090 |
Why?
|
False Positive Reactions | 1 | 2011 | 1004 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2017 | 1493 | 0.090 |
Why?
|
Proto-Oncogene Proteins | 2 | 2018 | 4677 | 0.080 |
Why?
|
Leukemia | 1 | 2016 | 1496 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2668 | 0.080 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7487 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2016 | 2593 | 0.080 |
Why?
|
Myelodysplastic Syndromes | 1 | 2017 | 1255 | 0.080 |
Why?
|
Thrombocytopenia | 2 | 2012 | 1136 | 0.080 |
Why?
|
Arrhythmias, Cardiac | 1 | 2017 | 2144 | 0.080 |
Why?
|
Lymph Nodes | 2 | 2011 | 3409 | 0.080 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 862 | 0.080 |
Why?
|
Lymphoma, B-Cell | 1 | 2013 | 917 | 0.080 |
Why?
|
Immunotherapy | 2 | 2019 | 4057 | 0.080 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 5045 | 0.080 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2008 | 220 | 0.070 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2021 | 671 | 0.070 |
Why?
|
Administration, Oral | 4 | 2019 | 3944 | 0.070 |
Why?
|
Retrospective Studies | 11 | 2021 | 71483 | 0.070 |
Why?
|
Bone Marrow | 2 | 2019 | 2938 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1597 | 0.070 |
Why?
|
Lymphatic Irradiation | 1 | 2005 | 104 | 0.070 |
Why?
|
Peptides | 1 | 2018 | 4424 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2008 | 616 | 0.070 |
Why?
|
Combined Modality Therapy | 4 | 2018 | 8896 | 0.070 |
Why?
|
Sulfonamides | 1 | 2014 | 1938 | 0.070 |
Why?
|
Survival Analysis | 4 | 2017 | 10507 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2004 | 74 | 0.060 |
Why?
|
Thiazoles | 1 | 2011 | 1510 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3266 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2018 | 5982 | 0.060 |
Why?
|
Antibodies, Neoplasm | 1 | 2004 | 311 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 4 | 2017 | 20308 | 0.060 |
Why?
|
Adolescent | 6 | 2019 | 84718 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2014 | 2535 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6765 | 0.050 |
Why?
|
Positron-Emission Tomography | 3 | 2014 | 6170 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2019 | 1908 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8638 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3281 | 0.050 |
Why?
|
Disease Progression | 5 | 2019 | 13298 | 0.050 |
Why?
|
Neutropenia | 2 | 2017 | 871 | 0.050 |
Why?
|
Anthracyclines | 1 | 2022 | 254 | 0.050 |
Why?
|
Pneumonia | 1 | 2012 | 2080 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2021 | 11239 | 0.050 |
Why?
|
Benzylamines | 2 | 2012 | 230 | 0.050 |
Why?
|
DNA | 1 | 2013 | 7172 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2019 | 69 | 0.040 |
Why?
|
Imidazolines | 1 | 2018 | 17 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 10857 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 205 | 0.040 |
Why?
|
Heart Failure | 1 | 2022 | 10040 | 0.040 |
Why?
|
Cohort Studies | 3 | 2019 | 39292 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 696 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 745 | 0.040 |
Why?
|
Signal Transduction | 2 | 2018 | 23950 | 0.040 |
Why?
|
Depsipeptides | 1 | 2018 | 88 | 0.040 |
Why?
|
Risk Assessment | 1 | 2019 | 23284 | 0.040 |
Why?
|
Prospective Studies | 6 | 2022 | 50597 | 0.040 |
Why?
|
Cisplatin | 1 | 2004 | 1651 | 0.040 |
Why?
|
Diarrhea | 2 | 2019 | 1354 | 0.040 |
Why?
|
Ki-67 Antigen | 1 | 2019 | 629 | 0.040 |
Why?
|
Ikaros Transcription Factor | 1 | 2018 | 226 | 0.040 |
Why?
|
Biopsy | 2 | 2020 | 6766 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 14075 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2018 | 401 | 0.040 |
Why?
|
Sodium | 1 | 2022 | 1637 | 0.040 |
Why?
|
Dexamethasone | 1 | 2004 | 1939 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2014 | 6338 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2008 | 4422 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 2910 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4466 | 0.040 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 261 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1719 | 0.040 |
Why?
|
Dioxygenases | 1 | 2017 | 318 | 0.030 |
Why?
|
Antigens, CD19 | 1 | 2017 | 338 | 0.030 |
Why?
|
Anemia, Myelophthisic | 1 | 2014 | 6 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4226 | 0.030 |
Why?
|
Janus Kinase 2 | 1 | 2018 | 508 | 0.030 |
Why?
|
Tumor Lysis Syndrome | 1 | 2014 | 40 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 200 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 3970 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2014 | 193 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 764 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 933 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1767 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1418 | 0.030 |
Why?
|
Interleukins | 1 | 2017 | 799 | 0.030 |
Why?
|
Time Factors | 4 | 2019 | 41038 | 0.030 |
Why?
|
Diphtheria Toxin | 1 | 2013 | 262 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 325 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9556 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2165 | 0.030 |
Why?
|
Blood Component Removal | 1 | 2012 | 118 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1918 | 0.030 |
Why?
|
Random Allocation | 1 | 2016 | 2455 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2012 | 273 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2013 | 813 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2019 | 10803 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2951 | 0.030 |
Why?
|
Radiotherapy | 1 | 2018 | 1623 | 0.030 |
Why?
|
Mediastinum | 1 | 2012 | 262 | 0.030 |
Why?
|
International Agencies | 1 | 2011 | 229 | 0.020 |
Why?
|
Infusions, Subcutaneous | 1 | 2009 | 45 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4261 | 0.020 |
Why?
|
Indoles | 1 | 2018 | 1857 | 0.020 |
Why?
|
Platelet Count | 1 | 2012 | 794 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2303 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 4883 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1887 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2019 | 2936 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2018 | 1851 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 2244 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2012 | 1670 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4254 | 0.020 |
Why?
|
Spasm | 1 | 2008 | 107 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 227 | 0.020 |
Why?
|
Standard of Care | 1 | 2011 | 497 | 0.020 |
Why?
|
Panic Disorder | 1 | 2010 | 612 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2017 | 2015 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 585 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2017 | 1630 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1906 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2543 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2630 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 654 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3701 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2018 | 3507 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 7994 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1767 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2013 | 1936 | 0.020 |
Why?
|
Protein Binding | 1 | 2018 | 9639 | 0.020 |
Why?
|
HIV Infections | 1 | 2011 | 15538 | 0.020 |
Why?
|
Child | 2 | 2019 | 73636 | 0.020 |
Why?
|
Transplantation Chimera | 1 | 2008 | 623 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2017 | 3075 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2532 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12447 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2013 | 3878 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16959 | 0.020 |
Why?
|
Risk Factors | 3 | 2019 | 69553 | 0.020 |
Why?
|
Anemia | 1 | 2012 | 1403 | 0.020 |
Why?
|
Sleep Apnea Syndromes | 1 | 2010 | 861 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1346 | 0.020 |
Why?
|
Internet | 1 | 2016 | 3074 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17218 | 0.010 |
Why?
|
Headache | 1 | 2009 | 1109 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2008 | 936 | 0.010 |
Why?
|
Registries | 1 | 2017 | 7989 | 0.010 |
Why?
|
Alcoholism | 1 | 2010 | 1840 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 5833 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4306 | 0.010 |
Why?
|
Mice | 2 | 2018 | 80876 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 9774 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16306 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 2277 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 8992 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2009 | 11877 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9402 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18712 | 0.010 |
Why?
|
Massachusetts | 1 | 2008 | 8712 | 0.010 |
Why?
|
Animals | 2 | 2018 | 170486 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2012 | 5044 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 16008 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 20320 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 14712 | 0.010 |
Why?
|
Neoplasms | 1 | 2019 | 20172 | 0.010 |
Why?
|
United States | 1 | 2016 | 67165 | 0.010 |
Why?
|
Obesity | 1 | 2010 | 12031 | 0.010 |
Why?
|